

Oriol de Fabregues

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4080165/publications.pdf>

Version: 2024-02-01

39
papers

1,588
citations

394390

19
h-index

302107

39
g-index

41
all docs

41
docs citations

41
times ranked

2096
citing authors

#	ARTICLE	IF	CITATIONS
1	Constipation Predicts Cognitive Decline in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. <i>Journal of Parkinson's Disease</i> , 2022, 12, 315-331.	2.8	10
2	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson's Disease Patients: A 2-Year Follow-Up Study. <i>Diagnostics</i> , 2022, 12, 1147.	2.6	5
3	Falls Predict Acute Hospitalization in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, , 1-20.	2.8	5
4	Effects of COVID -19 pandemic and lockdown on people with multiple system atrophy participating in a therapeutic education program. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 78-80.	2.2	7
5	Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life. <i>Parkinson's Disease</i> , 2021, 2021, 1-16.	1.1	10
6	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Personalized Medicine</i> , 2021, 11, 626.	2.5	10
7	Predictors of Loss of Functional Independence in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. <i>Diagnostics</i> , 2021, 11, 1801.	2.6	9
8	Predictors of clinically significant quality of life impairment in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 118.	5.3	17
9	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Diagnostics</i> , 2021, 11, 2380.	2.6	2
10	Delineating the motor phenotype of SGCE-myoclonus dystonia syndrome. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 165-174.	2.2	7
11	Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series. <i>Brain and Behavior</i> , 2020, 10, e01596.	2.2	9
12	Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa. <i>Journal of Neurology</i> , 2020, 267, 3400-3410.	3.6	3
13	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 151-157.	2.2	71
14	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2019, 126, 1599-1608.	2.8	11
15	Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 3-12.	2.2	26
16	COPPADIS 2015 (Cohort of Patients with Parkinson's Disease) Tj ETQq0 0 0 rgBT /Overlock 1000 subjects included. Results from the baseline evaluation. <i>European Journal of Neurology</i> , 2019, 26, 1399-1407.	3.3	32
17	Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 16-23.	2.2	32
18	Sleep Quality and Levodopa Intestinal Gel Infusion in Parkinson's Disease: A Pilot Study. <i>Parkinson's Disease</i> , 2018, 2018, 1-6.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Myoclonus-Dominant Corticobasal Degeneration. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 649-652.	1.5	1
20	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 13-20.	2.2	149
21	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. <i>ENeurologicalSci</i> , 2017, 8, 44-53.	1.3	10
22	Long-term safety and effectiveness of levodopa-carbidopa intestinal gel infusion. <i>Brain and Behavior</i> , 2017, 7, e00758.	2.2	32
23	An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients. <i>Advances in Therapy</i> , 2017, 34, 1741-1752.	2.9	24
24	COPPDIS-2015 (COhort of Patients with PARKinson's Disease in Spain, 2015), a global "clinical evaluations, serum biomarkers, genetic studies and neuroimaging" prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. <i>BMC Neurology</i> , 2016, 16, 26.	1.8	66
25	Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0132368.	2.5	67
26	Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 871-876.	2.2	79
27	Remote control of apomorphine infusion rate in Parkinson's disease: Real-time dose variations according to the patients' motor state. A proof of concept. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 996-998.	2.2	12
28	Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1170-1176.	2.2	43
29	The Onset of Non-motor Symptoms in Parkinson's disease (ONSET PD Study). <i>Movement Disorders</i> , 2015, 30, 229-237.	3.9	402
30	Two novel SCN1A mutations identified in families with familial hemiplegic migraine. <i>Cephalalgia</i> , 2014, 34, 1062-1069.	3.9	26
31	Progressive Presynaptic Dopaminergic Deterioration in Huntington Disease. <i>Clinical Nuclear Medicine</i> , 2014, 39, e227-e228.	1.3	6
32	Novel SCN1A mutation in the IFMT motif of the $\alpha 1$ subunit of the voltage-gated NaV1.1 channel causing familial hemiplegic migraine. <i>Journal of Headache and Pain</i> , 2013, 14, .	6.0	1
33	Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert. <i>Journal of Neurology</i> , 2012, 259, 1668-1672.	3.6	54
34	Age at Onset in LRRK2-Associated PD is Modified by SNCA Variants. <i>Journal of Molecular Neuroscience</i> , 2012, 48, 245-247.	2.3	34
35	Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: The ANIMO study. <i>Movement Disorders</i> , 2012, 27, 211-218.	3.9	105
36	Continuous Dopaminergic Stimulation. <i>Neurologist</i> , 2011, 17, S30-S37.	0.7	11

#	ARTICLE	IF	CITATIONS
37	Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: Impact on control of fluctuations and quality of life. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 218-221.	2.2	52
38	Pleuropulmonary Toxicity of Another Anti-Parkinson's Drug: Cabergoline. <i>Open Respiratory Medicine Journal</i> , 2009, 3, 90-93.	0.4	6
39	Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition?. <i>Journal of the Neurological Sciences</i> , 2000, 176, 65-69.	0.6	113